Glenmark announces 400 mg 'FabiFlu' for COVID 19 treatment - Tv9
Sat, Aug 08, 2020, 05:52 AM
Drug firm Glenmark Pharmaceuticals has come out launching a 400 mg version of oral antiviral drug Favipiravir with brand name FabiFlu. It can be used for the treatment of mild and moderate coronavirus in India. The drug is already available in 200 mg dosage.
Glenmark, the first Indian company, got the approval from the regulator Drugs Controller General of India for the usage of 400 mg dosage. The company has announced that the patients are required to use nine tablets on the first day and two tablets twice a day from the second day till the end of the course.